In the sprawling San Diego facility of Altos Labs, miniature human brains and beating hearts grow from stem cells. Susan Dominus observed these 'organoids' on The Daily, as billionaires like Jeff Bezos poach top scientists to build 'virtual cells' and run simulations that would take decades in a traditional lab.
But CEO Hal Barron is pivoting away from the immortality claims that have historically dogged the field. Dominus noted Barron frames the victory as extending ovarian viability or curing glaucoma - aiming to 'die healthy' rather than live forever. The science backing this shift is substantial: in 2016, Juan Carlos Izpisúa Belmonte applied a reduced dose of Nobel-winning reprogramming factors to fast-aging mice. They lived longer, looked younger, and healed faster without triggering the monstrous tumors of earlier attempts.
"Altos CEO Hal Barron is taking the opposite track, focusing on incremental gains rather than a 150-year lifespan."
- Susan Dominus, The Daily
This pragmatic reframing faces skepticism from within medicine. On The Peter Attia Drive, physician Peter Attia warns that public excitement around genetic and cellular manipulation often overlooks critical limitations. For most chronic diseases, he argues, measuring observable biological output - like artery imaging or insulin resistance - is more actionable than genetic predictions. The Human Genome Project, completed in 2003, failed to deliver on broad promises of predicting complex diseases.
Attia separates test utility into a matrix of effect size and actionability. High-penetrance mutations like BRCA1, which dictate specific surgeries, sit in the top-right corner. At the opposite end, he dismisses functional medicine staples like MTHFR, which appear in up to 40% of the population and rarely drive meaningful disease. Using them to justify bespoke supplement protocols is often more about marketing than biology.
The gap between consumer perception and clinical reality is dangerous. Attia warns that products like 23andMe scan for common 'snips' rather than sequencing full genes. A consumer test might check only three BRCA mutations out of thousands of pathogenic variants, creating a false negative.
"If a result doesn't change a medical decision, the test is noise."
- Peter Attia, The Peter Attia Drive
The billionaires' race is now between two visions: one aiming for incremental, disease-specific victories to avoid regulatory backlash, and another, embodied by controversial figures like Harvard's David Sinclair, still branded with immortality hype. The field's ultimate impact may depend less on cellular reprogramming and more on whether it can reprogram its own public narrative.
